Home Cart Sign in  
Chemical Structure| 1223403-58-4 Chemical Structure| 1223403-58-4

Structure of Larotrectinib
CAS No.: 1223403-58-4

Chemical Structure| 1223403-58-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LOXO-101 is an ATP-competitive inhibitor of TRK with IC50 of nanomolar range for all the family members.

Synonyms: LOXO-101; ARRY-470; Vitrakvi

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Larotrectinib

CAS No. :1223403-58-4
Formula : C21H22F2N6O2
M.W : 428.44
SMILES Code : FC1=CC=C(C([C@H]2CCCN2C3=NC4=C(C=NN4C=C3)NC(N5CC[C@@H](C5)O)=O)=C1)F
Synonyms :
LOXO-101; ARRY-470; Vitrakvi
InChI Key :NYNZQNWKBKUAII-KBXCAEBGSA-N
Pubchem ID :46188928

Safety of Larotrectinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Related Pathways of Larotrectinib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
143B/NGF cells 10-100 μM 24 or 48 hours To evaluate the effect of Larotrectinib on the viability of 143B/NGF cells, results showed that Larotrectinib had no cytotoxic effects on the cells PMC11379077
BaF3/RET(D898_E901del)/ETV6::NTRK3 cells 100 nM 3 days To validate the efficacy of selpercatinib in combination with larotrectinib or entrectinib on cells containing both RET and NTRK3 oncogenes. Results showed that the combination of selpercatinib with larotrectinib or entrectinib significantly reduced the IC50 values to 10 nM and 1.8 nM, respectively. PMC10912412
BaF3/RET(D898_E901del)/ETV6::NTRK3/EML4::ALK cells 100 nM 3 days To validate the efficacy of selpercatinib in combination with larotrectinib or entrectinib on cells containing RET, NTRK3, and ALK oncogenes. Results showed that the combination of selpercatinib with entrectinib had the lowest IC50 value (14.19 nM) and could completely suppress these cells at 75 nM. PMC10912412
NthyTPR-NTRK cells 50 μM Larotrectinib restored 125I uptake in NthyTPR-NTRK cells, mediated by the NIS. PMC8439610
IRC and KM12 cells 1-5000 nM 72 hours To assess the effect of Selpercatinib on the growth inhibition and TRK-mediated signaling in NTRK fusion-positive tumor cells. Results showed that Selpercatinib significantly inhibited tumor cell growth and TRK signaling. PMC11300601

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice B16 melanoma model Oral 200 mg/kg Once daily for 60 days Larotrectinib combined with immunotherapy significantly increased the complete remission rate of melanoma and achieved durable cure PMC11377935
SCID mice Prostate cancer xenograft model Subcutaneous injection 300 mg/kg Every 24 hours for 28 days Larotrectinib combined with ML210 significantly inhibited tumor growth PMC10782585
Nude mice Osteosarcoma xenograft model Oral 50 mg/kg Three times a week for four weeks To evaluate the effect of Larotrectinib on NGF-mediated tumor growth, results showed that Larotrectinib significantly inhibited tumor growth PMC11379077
Mice Wild-type and genetically modified mice Oral 10 mg/kg Single dose, lasting 1 hour or 8 hours To investigate the effects of ABCB1 and ABCG2 on the oral bioavailability and tissue distribution of Larotrectinib, results showed that ABCB1 and ABCG2 significantly limited the oral bioavailability and brain accumulation of Larotrectinib PMC7279963
Nude mice (BALB/c) HCT116 xenograft model Intragastric administration 20 mg/kg Twice daily for 3 weeks Lar significantly suppressed tumour volume and weight in the HCT116 xenograft model and activated autophagy through the AMPK/mTOR signalling pathway. PMC9639042

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.33mL

0.47mL

0.23mL

11.67mL

2.33mL

1.17mL

23.34mL

4.67mL

2.33mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories